Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan.

Kiyoshi TakamatsuTakashi MikiKentaro MiyazakiAtsuki HashimotoWeizhong HeXuegong Wang

Published in: Climacteric : the journal of the International Menopause Society (2024)

Oral fezolinetant at once-daily doses of 15 or 30 mg was efficacious and well tolerated for treatment of mild, moderate and severe VMS associated with menopause in this Japanese study.

Keyphrases

phase ii study
physical activity
open label
squamous cell carcinoma
clinical trial
early onset